Bogotá, August 2018. Colombian patients suffering from a type of lung cancer now have the possibility to access an innovative immunotherapy treatment, pembrolizumab (Keytruda®), in combination with platinum and premetrexed for the first-line treatment of lung cancer of cells not small, advanced or metastatic, not scaly, without EGFR and ALK aberrations, in the first treatment line.
This treatment could reduce the risk of death by 51%, according to the results presented at the annual meeting of the American Association for Cancer Research (AACR) and simultaneously published in the prestigious scientific journal New England Journal of Medicine. It is a treatment that can improve the survival indicator of patients suffering from this disease and the response rates of this type of tumor.
Lung cancer causes six thousand new cases per year and represents the second cause of death among men and the fifth among women in our country. Indeed, lung cancer is recognized as one of the most deadly in the world, claiming more than 1.59 million lives per year. In Colombia, according to the Ministry of Health and Social Protection, about 3082 people suffer from this disease, the third most common among men and the fourth among women. It is estimated that 1 in 5 cancer deaths are caused by lung cancer.
Immunotherapy has become a fundamental pillar in cancer treatment, which, through medication, generates an optimization of the immune system's own reactions so that it can reduce the growth and maturation of tumor cells. . This approach, in combination with other traditional treatments, such as chemotherapy, revolutionizes the way this disease is treated.
"The first level of scientific evidence available today is strong in demonstrating that the combination of pembrolizumab and chemotherapy is a revolutionary breakthrough in the treatment of patients with non-squamous non-small cell lung cancer, with the possibility of continuing These people and improve the quality of their lives, "said Dr. Camilo Moreno, medical director of MSD Oncology. He added that "this combination changes the paradigm of treating patients with this type of lung cancer, regardless of the expression level of the PD-L1 biomarker in the first line".
Comparable combination alternatives are evaluated in other types of tumors with interesting preliminary signals of response, which will be possible in the future, providing greater opportunities to extend patients' lives and combat this disease.
Our focus on cancer
Our goal is to turn advanced science into biomedical innovations to help people with cancer around the world. For MSD Oncology, helping people to fight cancer is our passion, supporting the affordability of our anti-cancer drugs is our commitment and research on immuno-oncology is our approach to possible new hope for people with cancer. Visit www.merck.com/clinicaltrials for more information about our oncology clinical trials
The MSD of today is a world leader in health care that works to make the world healthy. MSD is known as Merck in the United States and Canada. Through our prescribed medicines, vaccines, biological therapies and products for the health of consumers and animals, we work together with our customers and we are active in more than 140 countries to offer innovative health solutions. We also demonstrate our commitment to improve access to healthcare through policies, programs & # 39; s and far-reaching partnerships. For more information, visit www.msd.com.co Situation Adult population cancer: https://cuentadealtocosto.org/site/images/Libro%20C%C3%A1ncer%202015/Situacion_Cancer_Poblacion_Adulta_Web%20actualizacion_2016.pdf  Gandhi L et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med 2018 DOI: 10.1056 / NEJMoa1801005  Pharma Times. Keytruda / chemo combination reduces risk of death in NSCLC http://www.pharmatimes.com/news/keytrudachemo_combo_cut_risk_of_death_in_nsclc_1232128  Cancer.org. Estimated numbers of new cancers and deaths in Latin America and the Caribbean, both genders, 2012. Available at: http://canceratlas.cancer.org/image-text/?id=206&ref=205  Situation Adult population cancer: https://cuentadealtocosto.org/site/images/Libro%20C%C3%A1ncer%202015/Situacion_Cancer_Poblacion_Adulta_Web%20actualizacion_2016.pdf  Chemo combination reduces risk of death in NSCLC: http://www.pharmatimes.com/news/keytrudachemo_combo_cut_risk_of_death_in_nsclc_1232128
Photo: Tomada the sintesis.mx